Brought to you by:

VYNE Therapeutics

VYNE Therapeutics develops therapies for immuno-inflammatory conditions. 

Darts failing to hit bullseye
Biotech

2025's top 10 clinical trial flops

Fierce Biotech looks back at 10 of the most impactful and interesting clinical failures of 2025.
Vine jungle rainforest

Vyne's BET inhibitor fails phase 2 vitiligo trial, sinking stock

Jul 30, 2025 9:35am
Vine jungle rainforest

Vyne prunes psoriasis trial, but keeps faith in BET inhibitor

Jul 2, 2025 10:33am
Vine jungle rainforest

Vyne’s psoriasis drug hit with FDA hold over testicular toxicity

Apr 25, 2025 9:25am
Vine jungle rainforest

Vyne swings behind BET, seeks partner for failed eczema drug

Mar 10, 2023 9:30am
uproot tree

Vyne to reevaluate pipeline after eczema fail uproots plans

Aug 10, 2022 11:23am